New possibilities of therapy for recurrent vulvovaginal infections: Analysis and discussion of the results of the BIOS-2 multicenter study
Objective. To compare the efficacy of drugs to restore the vaginal microflora, such as gynoflor e, oral lactobacilli, and ascorbic acid, in the treatment of chronic recurrent vaginal inflammatory and noninflammatory diseases at treatment stage 2. Subject and methods. One hundred and sixty-six patients (mean age 31±7 years) with recurrent bacterial infections were examined. After the first stage of fluomisin treatment for bacterial vaginosis or vaginitis, Group 1 was randomly assigned gynoflor e, Group 2 was given other Lactobacillus preparations; Group 3 was untreated. The efficiency of restorative therapy and the rate of recurrences were estimated during visits 3 and 4 (at a 60-day interval). Results. The efficiency of using gynoflor e and other restorative drugs at treatment stage 2 showed that the clinical and laboratory effects were achieved at visit 3 in 53 and 55% of the patients with recurrent vaginitis/bacterial vaginosis, respectively. However, at visit 4, the patients treated with other eubiotics were noted to have a lower proportion of lactobacilli than those who used gynoflor e, which may be a prerequisite for an early recurrence of bacterial vaginosis. Conclusion. As compared with other treatment regimens, this therapy using fluomisin at treatment stage 1 and gynoflor e at stage 2 for recurrent vaginal infections proved to be effective in 85% of the patients, simultaneously demonstrating a better trend occurred in the recovery of the natural vaginal flora and halving the number of recurrences.